Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEMDNASDAQ:ECORNASDAQ:NEPHNASDAQ:PAVM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$1.76-10.7%$2.92$1.75▼$8.44$3.54M1.89215,478 shs65,076 shsECORelectroCore$5.09-5.2%$5.77$4.47▼$19.49$37.77M0.7996,768 shs66,981 shsNEPHNephros$3.87-3.5%$2.38$1.36▼$4.26$41.02M0.9614,434 shs59,165 shsPAVMPAVmed$0.64-5.9%$0.68$0.55▼$1.90$10.91M1.06131,728 shs152,526 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical-2.48%-27.04%-40.55%-34.09%-52.88%ECORelectroCore-5.12%+0.19%+13.77%-37.27%-17.51%NEPHNephros+5.53%+17.94%+84.79%+152.20%+84.79%PAVMPAVmed-1.68%+7.43%-6.18%+2.79%-35.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEMDAethlon Medical3.1101 of 5 stars3.55.00.00.02.50.01.3ECORelectroCore2.8184 of 5 stars3.52.00.00.03.32.50.6NEPHNephros1.8683 of 5 stars3.53.00.00.01.90.80.0PAVMPAVmed3.781 of 5 stars3.53.00.04.31.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical 3.00Buy$56.003,081.82% UpsideECORelectroCore 3.00Buy$25.50397.56% UpsideNEPHNephros 3.00Buy$5.0033.16% UpsidePAVMPAVmed 3.00Buy$19.002,878.06% UpsideCurrent Analyst Ratings BreakdownLatest PAVM, ECOR, NEPH, and AEMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.50 ➝ $19.004/21/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $19.503/13/2025ECORelectroCoreLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $26.003/13/2025ECORelectroCoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon Medical$570K6.21N/AN/A$2.19 per share0.80ECORelectroCore$26.46M1.44N/AN/A$1.24 per share4.13NEPHNephros$15.52M2.57N/AN/A$0.80 per share4.69PAVMPAVmed$1.99M5.47N/AN/A($3.35) per share-0.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$12.21M-$12.64N/AN/AN/AN/A-153.96%-109.13%6/26/2025 (Estimated)ECORelectroCore-$18.83M-$1.56N/AN/AN/A-54.40%-154.45%-69.16%8/6/2025 (Estimated)NEPHNephros-$1.58M$0.07N/A∞N/A-6.86%-11.39%-8.30%8/6/2025 (Estimated)PAVMPAVmed-$64.18M$0.71N/AN/AN/A602.97%N/A-92.36%8/12/2025 (Estimated)Latest PAVM, ECOR, NEPH, and AEMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/26/2025Q4 2025AEMDAethlon Medical-$0.13N/AN/AN/AN/AN/A5/15/2025Q1 2025NEPHNephros-$0.0050$0.0526+$0.0576$0.05$3.67 million$4.88 million5/7/2025Q1 2025ECORelectroCore-$0.56-$0.47+$0.09-$0.47$6.93 million$6.72 million3/24/2025Q4 2024NEPHNephros-$0.01$0.03+$0.04$0.03$3.67 million$3.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/AECORelectroCoreN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A2.802.80ECORelectroCoreN/A2.121.87NEPHNephrosN/A6.954.02PAVMPAVmedN/A0.060.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%ECORelectroCore26.74%NEPHNephros41.10%PAVMPAVmed19.93%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical1.20%ECORelectroCore19.70%NEPHNephros6.70%PAVMPAVmed7.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical102.01 million14.30 millionNo DataECORelectroCore507.42 million5.35 millionNot OptionableNEPHNephros3010.60 million10.11 millionNot OptionablePAVMPAVmed9017.09 million9.82 millionOptionablePAVM, ECOR, NEPH, and AEMD HeadlinesRecent News About These CompaniesPAVmed (NASDAQ:PAVM) and Lombard Medical (OTCMKTS:EVARF) Critical AnalysisJune 10 at 2:43 AM | americanbankingnews.comPAVmed (NASDAQ:PAVM) Price Target Lowered to $19.00 at Ascendiant Capital MarketsJune 8, 2025 | americanbankingnews.comPAVmed subsidiary Veris Health partners with Ohio State University cancer centerJune 5, 2025 | finance.yahoo.comPAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove ...June 5, 2025 | morningstar.comPAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteJune 3, 2025 | prnewswire.comLucid Diagnostics to Join Russell 2000® and Russell 3000® IndexesMay 27, 2025 | prnewswire.comEarnings call transcript: PAVmed’s Q1 2025 sees strong net income and strategic shiftsMay 16, 2025 | investing.comPAVmed Inc. (NASDAQ:PAVM) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comPAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial FortificationMay 16, 2025 | finance.yahoo.comPAVmed Inc. (PAVM) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comPAVmed Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 15, 2025 | prnewswire.comPAVmed Q1 2025 Earnings PreviewMay 14, 2025 | msn.comLucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | prnewswire.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025April 30, 2025 | prnewswire.comPAVmed (PAVM) Upgraded to Buy: Here's What You Should KnowApril 28, 2025 | zacks.comPAVmed switches to new accounting firm post-acquisitionApril 27, 2025 | investing.comNCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERDApril 24, 2025 | prnewswire.comLucid Diagnostics Announces Closing of Public Offering of Common StockApril 11, 2025 | prnewswire.comLucid Diagnostics Shares Drop After $15M Public Offering PricedApril 10, 2025 | marketwatch.comLucid Diagnostics Announces Pricing of Public Offering of Common StockApril 9, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNextracker’s Solar Surge: Will It Shatter Its All-Time High?By Thomas Hughes | May 18, 2025View Nextracker’s Solar Surge: Will It Shatter Its All-Time High?Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?By Leo Miller | May 16, 2025View Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?Broadcom Earnings Preview: AVGO Stock Near Record HighsBy Leo Miller | June 3, 2025View Broadcom Earnings Preview: AVGO Stock Near Record Highse.l.f. Beauty Sees Record Surge After Earnings, Rhode DealBy Leo Miller | May 30, 2025View e.l.f. Beauty Sees Record Surge After Earnings, Rhode DealPAVM, ECOR, NEPH, and AEMD Company DescriptionsAethlon Medical NASDAQ:AEMD$1.76 -0.21 (-10.66%) Closing price 04:00 PM EasternExtended Trading$1.80 +0.03 (+1.99%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.electroCore NASDAQ:ECOR$5.09 -0.28 (-5.21%) Closing price 04:00 PM EasternExtended Trading$5.11 +0.02 (+0.31%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.Nephros NASDAQ:NEPH$3.87 -0.14 (-3.49%) Closing price 04:00 PM EasternExtended Trading$3.86 0.00 (-0.13%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.PAVmed NASDAQ:PAVM$0.64 -0.04 (-5.88%) Closing price 04:00 PM EasternExtended Trading$0.66 +0.02 (+2.74%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
